PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.3% – Should You Sell?

PDS Biotechnology Corporation (NASDAQ:PDSB) fell 5.3% during trading on Wednesday . The stock traded as low as $0.90 and last traded at $0.9090. 659,799 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 999,362 shares. The stock had previously closed at $0.96.

Analyst Ratings Changes

Several research firms recently commented on PDSB. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a report on Wednesday, April 15th. Finally, Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Price Performance

The company has a market cap of $50.74 million, a PE ratio of -1.36 and a beta of 1.57. The business’s 50 day moving average price is $1.12 and its 200-day moving average price is $0.90. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. As a group, analysts forecast that PDS Biotechnology Corporation will post -0.52 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of PDS Biotechnology by 25.0% during the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares during the period. Virtu Financial LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter valued at approximately $25,000. Armistice Capital LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter valued at approximately $2,182,000. Commonwealth Equity Services LLC increased its stake in shares of PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after buying an additional 106,300 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after buying an additional 38,399 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.